Last reviewed · How we verify
Amosartan Plus Tab.
At a glance
| Generic name | Amosartan Plus Tab. |
|---|---|
| Also known as | Amlodipine camsylate, Losartan potassium, Chlorthalidone |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease (PHASE4)
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
- Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB (PHASE2)
- The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amosartan Plus Tab. CI brief — competitive landscape report
- Amosartan Plus Tab. updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI